HIV Infections
Conditions
Keywords
Pulmonary Alveoli, Macrophage Activation, Interferon-gamma, Recombinant, Injections, Subcutaneous, Aerosols, Acquired Immunodeficiency Syndrome
Brief summary
To determine safety and tolerance of administering aerosolized recombinant interferon gamma (IFN-gamma) for 4 weeks in patients with AIDS. To examine activation of alveolar macrophages by aerosolized IFN-gamma administration. To determine if subcutaneous (SC) injection of IFN-gamma can activate alveolar macrophages in AIDS patients.
Interventions
DRUGInterferon gamma-1b
Sponsors
Amgen
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Patients must have: * Diagnosis of AIDS with one or more opportunistic infections. * Kaposi's sarcoma with prior history of opportunistic infection. * Stable dose of zidovudine (AZT) therapy. * Preserved pulmonary, renal and hepatic function.
Exclusion criteria
Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Presence of active infection. * Active opportunistic infections. * Cardiac disease. * Central nervous system disorders. * History of seizures. * Irreversible airway disease. Patients with the following are excluded: * Co-existing conditions and symptoms listed in Patient Exclusion Co-existing Conditions. Prior Medication: Excluded within 4 weeks of study entry: * Immunosuppressive therapy. * Cytotoxic therapy. * Excluded: * Interferon gamma therapy.
Countries
United States
Outcome results
None listed